Filing summary
Entity and period: The supplied filing is Tekmira Pharmaceuticals Corporation’s Form 10-K for the fiscal year ended December 31, 2014, including fourth-quarter results. It is not filed under the name Arbutus Biopharma Corp; investors should verify the requested company and filing match. Tekmira completed its merger with OnCore Biopharma on March 4, 2015, after year-end, and subsequently focused its strategy on hepatitis B virus (HBV) therapies.
Financial results and liquidity
Unless otherwise noted, amounts are in U.S. dollars. The business was development-stage and had no commercial product revenues; revenue came primarily from collaborations, government contracts, licensing, milestones and royalties.
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $15.0 million | $15.5 million |
| Operating expenses | $47.9 million | $27.6 million |
| Operating loss | $33.0 million | $12.2 million |
| Net loss | $38.8 million | $14.1 million |
| Basic and diluted loss per share | $1.80 | $0.92 |
| Operating cash flow | $(12.4) million | $(6.7) million |
| Cash and cash equivalents | $72.2 million | $68.7 million |
| Short-term investments | $40.0 million | — |
| Total assets / total liabilities | $118.2 million / $30.1 million | $71.7 million / $12.5 million |
Revenue declined modestly while operating expenses rose substantially, chiefly from higher research and development spending, expanded clinical work, increased staffing and stock-based compensation. Research and development expense increased to $38.7 million from $21.5 million. The 2014 net loss also included a $10.4 million non-cash loss from the increase in warrant-liability fair value, partly offset by $4.1 million of foreign-exchange gains. The filing reports no conventional borrowing balance in the presented liabilities; liabilities included payables, deferred revenue and warrant liabilities.
Investing cash outflow was $43.0 million, primarily from purchases of guaranteed investment certificates; financing cash inflow was $60.7 million, including $56.5 million net proceeds from a March 2014 share offering. Year-end cash plus short-term investments was $112.2 million. Management stated that resources were sufficient for at least the next 12 months, while warning that substantial additional funding would be needed for continued pipeline development. Net liquidity, defined as cash and short-term investments less accounts payable and accrued liabilities, was $102.8 million.
Fourth-quarter net loss was $6.2 million, or $0.27 per share, versus $2.6 million, or $0.15 per share, in Q4 2013. The filing gives Q4 2014 revenue as $4.35 million in its interim data and approximately $4.4 million in its quarterly table, but elsewhere states $4.6 million; the filing text does not provide a clear, consistent Q4 revenue value. Q4 2014 expenses were higher year over year, reflecting HBV clinical preparation, the HCC study and Ebola-Guinea manufacturing.
Material changes and business developments
- Tekmira’s revenue mix shifted: Department of Defense (DoD) revenue was $8.4 million, or 56% of 2014 revenue, compared with $9.8 million, or 63%, in 2013. Monsanto, Dicerna and Spectrum generated additional 2014 revenue; the prior-year $5.0 million Alnylam milestone did not recur.
- Tekmira raised $60.5 million gross through a March 2014 public share offering. Common shares outstanding were 22.4 million at December 31, 2014; the filing reports 46.6 million outstanding as of March 9, 2015, following the OnCore transaction and other share activity.
- The March 2015 OnCore merger added HBV programs and changed the company’s strategic emphasis. Tekmira issued approximately 24.0 million shares to OnCore holders; estimated acquisition consideration was $381.9 million, subject to incomplete purchase accounting at filing. These are post-period developments and are not included in 2014 operating results.
- Deferred revenue increased to $15.7 million from $3.5 million, mainly reflecting Monsanto and Dicerna payments to be recognized over future service or option periods.
- Tekmira’s TSX listing was voluntarily delisted effective March 3, 2015; the filing said its NASDAQ listing would continue.
Outlook, risks and contingencies
- HBV strategy: Management aimed to build combination therapies addressing viral replication, host immune response and cccDNA. Two TKM-HBV formulations entered a Phase I study in early 2015; management expected to select a formulation for a multiple-dose patient study in the second half of 2015. Other stated targets included an OCB-030 IND and study by year-end 2015, Phase I initiation for a capsid inhibitor in 2016, and an IND for cccDNA formation inhibitors in 2017. These are forward-looking plans, not assured outcomes.
- Other programs: Management expected TKM-HTG IND submission in the second half of 2015 and final TKM-PLK1 GI-NET/ACC study data in the second half of 2015. Ebola-Guinea study results were also expected in that period. TKM-Ebola’s healthy-volunteer multiple-dose study remained under partial clinical hold; management cautioned that the hold might not be resolved.
- Funding and concentration: Tekmira relied significantly on collaborators and contracts, including the DoD, which supplied 56% of 2014 revenue. The DoD can suspend or cancel funding, and the timing and amount of future partner payments are uncertain. Management anticipated ongoing losses and substantial future capital needs.
- Legal matters: Tekmira disputed Alnylam’s refusal to pay a claimed $5.0 million milestone, which was not recorded as revenue; arbitration was scheduled for May 2015. UBC claimed $3.5 million plus unspecified royalties, interest and costs in a separate arbitration; Tekmira disputed the claim and recorded no estimated loss.
- Contractual and licensing exposure: The OnCore portfolio carries potentially significant development, sales milestone and royalty obligations to licensors, including NeuroVive, Cytos, Blumberg/Drexel and Enantigen’s former owners. Tekmira also faced a $2.0 million Enantigen-related payment due by March 31, 2015; failure to pay could result in loss of rights to certain HBV programs.
- Other risks: Drug candidates are early-stage and may fail in trials or face regulatory delays; commercialization and manufacturing depend partly on third parties. Integration of OnCore, intellectual-property challenges, competition, foreign-exchange exposure and potential dilution are additional risks. The filing reported effective disclosure controls and internal control over financial reporting, with an unqualified auditor opinion.
Important facts for investors to verify
- Confirm that this Tekmira 2014 Form 10-K is the intended filing for Arbutus Biopharma Corp.
- Reconcile the inconsistent Q4 2014 revenue disclosures and check the audited statements for the controlling figure.
- Review post-merger share count, final OnCore purchase accounting, integration costs and the combined company’s cash runway.
- Track clinical and regulatory milestones, especially TKM-HBV results and the TKM-Ebola partial clinical hold.
- Monitor resolution and potential financial consequences of the Alnylam and UBC arbitrations, and satisfaction of the Enantigen payment obligation.
- Assess future cash burn, dependence on DoD and other collaborators, and the timing and potential scale of acquired-program milestone and royalty obligations.